Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.42 |
| ▸ | ATF1 | P18846 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4812899 | 1.00 | ALDH1A1 (0.97) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL27681040 | 0.85 | ALDH1A1 (0.76) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL25689654 | 0.81 | ALDH1A1 (0.66) | ALDH1A1POLBSMN1; SMN2KMT2APTPN11 | |
| SCHEMBL25689688 | 0.79 | ALDH1A1 (0.63) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL25239083 | 0.76 | ALDH1A1 (0.62) | ALDH1A1POLBPTPN11MAPT | |
| SCHEMBL25689683 | 0.76 | ALDH1A1 (0.57) | ALDH1A1POLBSMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL9170525 | 0.74 | ALDH1A1 (0.60) | ALDH1A1POLBSMN1; SMN2PTPN11ATF1 | |
| SCHEMBL3712518 | 0.73 | POLB (0.57) | ALDH1A1POLBSMN1; SMN2PTPN11ATF1 | |
| SCHEMBL186135 | 0.73 | POLB (0.69) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL30331571 | 0.72 | POLB (0.78) | ALDH1A1POLBSMN1; SMN2PTPN11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432289-B2 | 5-Acylamino-1,1′-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2008-10-07 | — | — | US | disclosed |
| US-20040242868-A1 | 5-acylamino-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1435934-A1 | 5'-ACYLAMINO-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003032971-A1 | 5’-ACYLAMINO-1,1’-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242868-A1 | 5-acylamino-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | MAPK1, MAP3K1, MAPK7 | ALDH1A1 531/4885POLB 2401/4885SMN1; SMN2 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.